Long-term treatment with patisiran (Onpattro) led to modest changes for people with hereditary transthyretin amyloidosis ...

Rockville, MD , Jan. 07, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global Polyneuropathy Treatment Market is set to reach US$ 2.05 ...

AstraZeneca and Ionis are set fair for EU approval of Wainzua, their treatment for polyneuropathy associated with transthyretin-mediated amyloidosis (ATTR), after the EMA's human medicines ...

In the longest study of an RNAi therapeutic for any disease, patisiran treatment demonstrated modest improvements in patients ...

Riliprubart is under clinical development by Sanofi and currently in Phase III for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). According to GlobalData, Phase III drugs for Chronic ...

The outgoing U.S. Surgeon General made headlines when he called for a cancer warning on alcoholic beverages. But cancer is ...

If you're not a frequent Amazon customer, you're probably wondering what is Amazon Prime or if it's worth your money. Amazon Prime is a subscription service that gives members access to a variety ...

type of familial amyloidotic polyneuropathy (FAP) found in Japan and Europe as foci. We analysed the TTR gene haplotype of FAP patients from Japan, Portugal, Spain, and Sweden, and of Japanese and ...

Dianthus Therapeutics is advancing treatments for autoimmune diseases. Read why DNTH stock is receiving Buy ratings and price ...